ACA Marketplace
Covered with requirementsWhat you need to qualify
- Age 10 and older
- Diagnosis documented with a code
- Prior trial of 2 other GLP-1 medications (Victoza and Trulicity) for at least 90 days
Qualification pathways
You can qualify through any one of these.
T2DM with MASLD and overweight/obesity
All of:
- Diagnosis of type 2 diabetes mellitus
- Age >= 10 years
- Diagnosis of MASLD
- BMI 25-29.9 kg/m2 (overweight) or BMI >= 30 kg/m2 (obese)
- Not prescribed concurrently with another GLP-1 receptor agonist or DPP-4 inhibitor
- Dose does not exceed FDA-approved maximum (15 mg/week for adults, 10 mg/week for pediatrics)
- Failure of both preferred GLP-1s: liraglutide (Victoza) for >= 3 consecutive months, then Trulicity for >= 3 consecutive months, unless clinically significant adverse effects, both contraindicated, or member has CKD and request is for Ozempic injection
T2DM with MASH
All of:
- Diagnosis of type 2 diabetes mellitus
- Age >= 10 years
- Diagnosis of MASH
- Failure of >= 3 consecutive month trial of pioglitazone unless contraindicated or clinically significant adverse effects
- Not prescribed concurrently with another GLP-1 receptor agonist or DPP-4 inhibitor
- Dose does not exceed FDA-approved maximum (15 mg/week for adults, 10 mg/week for pediatrics)
- Failure of both preferred GLP-1s: liraglutide (Victoza) for >= 3 consecutive months, then Trulicity for >= 3 consecutive months, unless clinically significant adverse effects, both contraindicated, or member has CKD and request is for Ozempic injection
T2DM with ASCVD, high ASCVD risk, HFpEF, or CKD — agent with proven CV/renal benefit
All of:
- Diagnosis of type 2 diabetes mellitus
- Age >= 10 years
- Mounjaro is an agent with proven cardiovascular benefit per 2026 ADA guidelines
- Not prescribed concurrently with another GLP-1 receptor agonist or DPP-4 inhibitor
- Dose does not exceed FDA-approved maximum (15 mg/week for adults, 10 mg/week for pediatrics)
- Failure of both preferred GLP-1s: liraglutide (Victoza) for >= 3 consecutive months, then Trulicity for >= 3 consecutive months, unless clinically significant adverse effects, both contraindicated, or member has CKD and request is for Ozempic injection
Plus any one of:
- Established atherosclerotic cardiovascular disease (ASCVD)
- Indicators of high ASCVD risk (per Appendix D: age >= 55 with coronary/carotid/lower-extremity artery stenosis >50%, LVH, retinopathy, other end organ damage)
- Heart failure with preserved ejection fraction
- Chronic kidney disease
- Failure of >= 3 consecutive months of SGLT2 inhibitor or SGLT2 inhibitor-containing product, unless clinically significant adverse effects or all contraindicated
T2DM without ASCVD, high ASCVD risk, HFpEF, CKD, MASLD, or MASH — non-GLP-1 step therapy
All of:
- Diagnosis of type 2 diabetes mellitus
- Age >= 10 years
- No established ASCVD, indicators of high ASCVD risk, heart failure with preserved ejection fraction, CKD, MASLD, or MASH
- Failure of >= 3 consecutive month trial of two agents from any of the following classes: biguanides, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors or SGLT2 inhibitor-containing products, unless clinically significant adverse effects or all contraindicated
- Not prescribed concurrently with another GLP-1 receptor agonist or DPP-4 inhibitor
- Dose does not exceed FDA-approved maximum (15 mg/week for adults, 10 mg/week for pediatrics)
- Failure of both preferred GLP-1s: liraglutide (Victoza) for >= 3 consecutive months, then Trulicity for >= 3 consecutive months, unless clinically significant adverse effects, both contraindicated
Documentation to bring
- Office chart notes, lab results, or other clinical information supporting all approval criteria
- Documentation of type 2 diabetes mellitus diagnosis
- Documentation of member age (>= 10 years)
- Documentation of qualifying condition pathway (MASLD with overweight/obesity, MASH with pioglitazone trial/failure, ASCVD/high ASCVD risk/HFpEF/CKD with SGLT2i trial/failure, or two non-GLP-1 agent trial/failures)
- Documentation of failure of liraglutide (Victoza) for >= 3 consecutive months (unless excepted)
- Documentation of failure of Trulicity for >= 3 consecutive months after Victoza failure (unless excepted)
- Confirmation that requested product is not prescribed concurrently with another GLP-1 receptor agonist or DPP-4 inhibitor
Approval and renewal
- Initial approval: 12 months
- Renewal: every 12 months
- To renew, the plan looks for Member is responding positively to therapy. Continued therapy requires either (a) currently receiving medication via Centene benefit or previously met initial approval criteria, or (b) enrolled in a state with continuity of care regulations. No concurrent use with another GLP-1 or DPP-4 inhibitor.
Not covered when
- Concurrent use with another GLP-1 receptor agonist
- Concurrent use with a DPP-4 inhibitor
- Dose exceeding FDA-approved maximum recommended dose
- Type 1 diabetes
Policy note: Mounjaro is classified as a non-preferred GLP-1 receptor agonist requiring step therapy through liraglutide (Victoza) then Trulicity. Per 2026 ADA guidelines, Mounjaro was added as an agent with proven cardiovascular benefit. Age expansion to >= 10 years added per 2026 annual review. Mounjaro is a dual GLP-1/GIP receptor agonist but categorized under GLP-1 class policy. Pediatric maximum dose is 10 mg/week; adult maximum dose is 15 mg/week.
Policy effective February 26, 2026 · verified June 2, 2026 · source: CP.PMN.183.pdf